52 results about "Secretin" patented technology

Methods for aiding in the diagnosis of dysautonomic disorders and dysautonomic conditions and methods for treating individuals diagnosed as having a dysautonomic disorder or a dysautonomic condition. In one aspect, a diagnosis method comprising analyzing a stool sample of an individual for the presence of a biological marker wherein the quantity of the biological marker is an indication of whether the individual has, or can develop, a dysautonomic disorder or dysautonomic condition, as well as a therapeutic method for treating a dysautonomic disorder or dysautonomic condition by administration of, e.g., secretin, neuropeptides, peptides and / or digestive enzymes.

A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADHD, Autism and other PDD related disorders. In one aspect, a method for determining the efficacy of secretin, other neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with secretin, other neuropeptides, peptides, or digestive enzyme administration. In another aspect, a therapeutic method for treating an individual diagnosed with i PDD pervasive developmental disorder comprises determining the efficacy of secretin, other neuropeptides, peptides, and digestive enzyme administration for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering secretin, other neuropeptides, peptides, or digestive enzymes to the individual based on the determination of the measure of the individual's chymotrypsin level.

A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADHD, Autism and other PDD related disorders. In one aspect, a method for determining the efficacy of secretin, other neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with secretin, other neuropeptides, peptides, or digestive enzyme administration. In another aspect, a therapeutic method for treating an individual diagnosed with i PDD pervasive developmental disorder comprises determining the efficacy of secretin, other neuropeptides, peptides, and digestive enzyme administration for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering secretin, other neuropeptides, peptides, or digestive enzymes to the individual based on the determination of the measure of the individual's chymotrypsin level.

A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. In one aspect, a method for determining the efficacy of secretin, other neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with secretin, other neuropeptides, peptides, or digestive enzyme administration. In another aspect, a therapeutic method for treating an individual diagnosed with a PDD pervasive developmental disorder comprises determining the efficacy of secretin, other neuropeptides, peptides, and digestive enzyme administration for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering secretin, other neuropeptides, peptides, or digestive enzymes to the individual based on the determination of the measure of the individual's chymotrypsin level.

The invention relates generally to methods for treating acute pancreatitis in patients. The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising secretin and a pharmaceutically acceptable carrier.

A novel relationship between pancreatico-biliary secretion and autistic syndrome is disclosed. This relationship enables a novel therapy for the treatment of the symptoms of autistic syndromes, comprising the administration of a therapeutically effective, preferably intravenous, dose of secretin to an individual with autistic syndrome. The relationship further enables a differential diagnosis for autistic syndrome, comprising an analysis of an individual's blood and / or intestinal tissue for the presence of secretin and comparison of the level of secretin to known norms.

A complex is provided for the treatment of neurogenic conditions having the formula:where R1 isM is a metal ion Ca(II), Mg(II), Cu(II) or Ni(II); n is an integer 1 or 2; R is BBB peptide, transferrin, membrane transporter peptide, TAT peptide, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidegluconate, L-lactate, L-leucine, L-tryptophan, and L-glutamate; and R is coupled to M through a carboxylate moiety. Magnesium(II) represents the preferred metal ion as magnesium is known to have neuroprotective effects. The metal ion is in part chelated by a non-steroidal anti-inflammatory drug that does not inhibit platelet activity and includes salicylate and ibuprofenate. The complex also includes a ligand operative in transport across the blood brain barrier. A process for making an inventive complex includes the stoichiometric addition of ligands containing carboxylate groups to a solution of the metal ion. In instances where the metal ion is magnesium(II), a stoichiometric ratio of 1:1:1 is found between the non-steroidal anti-inflammatory ligand:magnesium(II):transporter ligand.

A compound is provided that has the formulaNH2CH2CH2CH2C(O)N—R  (I)where R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidetransferrin, glucosylamnine, amino saccharin, lactylamine, leucine, tryptophan, glutamate and amino cholines.

A compound is provided that has the formulaNH2CH2CH2CHR1C(O)N—R   (I)where R1 is p-chlorophenyl, R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptide transferrin, glucosylamine, amino saccharin, lactylamine, leucine, tryptophan, glutamate and amino cholines.

A compound of the formulawhere R1 is H, C1–C4 alkyl and OH; R2 in is H, C1–C4 alkyl and OH; R3 is H and C1–C4 alkyl; R4 is H and C1–C4 alkyl; n is an integer between 0 and 2 inclusive; R5 is a nullity, NHR7C(O)—, C6H4—, C6H4—O—; R7 is C2–C6 alkyl; and R6 is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine, blood brain barrier (BBB) peptide, membrane translocating peptide, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidegluconate, transferrin, glucosylamine, amino saccharin, saccharin ester, lactylamine, leucine, tryptophan, amino glutamate and amino cholines.

A compound of the formula where R1 is H, C1-C4 alkyl and OH; R2 in is H, C1-C4 alkyl and OH; R3 is H and C1-C4 alkyl; R4 is H and C1-C4 alkyl; n is an integer between 0 and 2 inclusive; R5 is a nullity, NHR7C(O)—, C6H4—, C6H4—O—; R7 is C2-C6 alkyl; and R6 is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine, blood brain barrier (BBB) peptide, membrane translocating peptide, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidegluconate, transferrin, glucosylamine, amino saccharin, saccharin ester, lactylamine, leucine, tryptophan, amino glutamate and amino cholines.

The invention provides a method for preparing mesenchymal stem cell secretin with low production cost and high product purity, a bioreactor technology is used for replacing a traditional cell culture bottle to prepare mesenchymal stem cell secretin, the cost and the required space can be greatly reduced; the used mesenchymal stem cells enables high compatibility, the mesenchymal stem cells is continuously stimulated in a safe mode to secrete the protein, and the output of mesenchymal stem cell secretin can be enhanced.

The treatment of schizophrenia by administration of secretin to a patient in need thereof is disclosed.

The present invention provides compositions and methods for preventing and treating gastrointestinal disorders by administering to a subject an effective amount of secretin either alone or in combination with an effective amount of oxytocin. The invention also provides compositions and methods for preventing and treating central nervous system disorders by administering to a subject an effective amount of secretin in combination with an effective amount of oxytocin. The invention further provides compositions and methods for treating and preventing a variety of autoimmune diseases by administering to a subject an effective amount of secretin in combination with an effective amount of oxytocin. Additionally, the invention provides compositions and methods for preventing and treating pain by administering to a subject using a combination of an effective amount of secretin and an effective amount of oxytocin. The invention also provides kits for use in treating and / or preventing gastrointestinal disorders, central nervous system disorders, autoimmune diseases and pain comprising a combination of secretin and oxytocin.

The present invention provides bacterial strains for secretion of soluble biologically active recombinant heterologous proteins into periplasm or on a surface / into a cultivation medium of bacteria. The invention exploits the secretion system of Gram-negative bacteria including periplasmic chaperones and usher / secretin proteins. For accomplishing the aim, the bacterial strains simultaneously express the fusion protein (signal peptide)-(mature hecterologous protein)-(subunit of a bacterial surface structure, Caf1), periplasmic chaperone specific for the subunit, and outer membrane usher / secretin protein specific for the subunit. Secretion of fusion proteins: (signal peptide of Caf1)-(mature human IL-1β)-(mature Caf1), (signal peptide of Caf1)-(mature human GM-CSF)-(mature Caf1), and (signal peptide of Caf1)-(mature human IL-1ra)-(mature Caf1) that were expressed in Escherichia coli simultaneously with the periplasmic chaperone Caf1M and the usher / secretin protein Caf1A are examples of the use of the invention.

The invention provides a solid phase method of secretin, which comprises the following steps: 1) selecting an appropriate solid phase carrier; 2) coupling amino acids one by one according to a solid phase synthetic method; 3) splitting for obtaining a crude peptide; 4) obtaining the secretin by purifying the crude peptide, wherein, the solid phase synthesis employs Fmoc-strategy, and false proline is used for replacing parts of serine in the peptide chain during the solid phase synthesis. The solid phase method of secretin provided by the invention has the advantages of simple operation, small impurity, easy purifying and high yield, and is beneficial to realization of industrialization.

The invention relates generally to methods for preventing post endoscopic retrograde cholangiopancreatography pancreatitis (ERCP). The method comprises administering a therapeutically effective amount of a pharmaceutical composition comprising secretin and a pharmaceutically acceptable carrier.

The invention belongs to the field of biotechnology, and specifically relates to a preparation method and application of an induced pluripotent stem cell secretin. The preparation method of the induced pluripotent stem cell secretin, provided by the invention, comprises treatment of induced pluripotent stem cells, proliferation of the induced pluripotent stem cells, acquisition, purification and concentration of the induced pluripotent stem cell secretin, that is, the induced pluripotent stem cell secretin is obtained by culturing the induced pluripotent stem cells, taking supernatant fluid, and performing filtration and concentration. The preparation method provided by the invention is simple and feasible, is suitable for large-scale production, and effectively improves the yield of the induced pluripotent stem cell secretin, and the induced pluripotent stem cell secretin prepared with the method provided by the invention can be effectively applied to health products and cosmetics.

The invention relates generally to methods for preventing post endoscopic retrograde cholangiopancreatography pancreatitis (ERCP). The method comprises administering a therapeutically effective amount of a pharmaceutical composition comprising secretin and a pharmaceutically acceptable carrier.

The invention belongs to the field of skincare products, in particular to an anti-aging skincare product containing epidermal stem cell secretin and a preparation method of the anti-aging skincare product. The skincare product is prepared from the following components by weight percentage: 0.000001-0.0005% of epidermal stem cell secretin, 2-8% of plant extract, 1-2% of squalane, 0.10-0.25% of EDTA-2Na, 5-10% of glycerol, 0.05-1% of poly-glutamic acid, 0.06-0.12% of K350, 2-6% of isopropyl myristate, 0.5-2% of cetearyl alcohol, 1-2% of polydimethylsiloxane and the balance of water, wherein the plant extract is prepared from semen adenantherae pavoninae, edgeworthia chrysantha, radix acanthopanacis senticosi, ilicis rotundae cortex and fructus rubi. The skincare product provided by the invention can significantly improve skin aging, delay aging, reduce the incidence of adverse reactions, is simple in preparation method and stable in property.

The invention discloses a method for large-scale production of mesenchymal stem cell secretin, comprising the following steps: 1) stem cells are cultured through a culture solution in a bioreactor, and the internal conditions of the bioreactor are 37 DEG C and 5 % carbon dioxide gas; 2) the stem cells obtained in the Step 1 are washed with a phosphate buffer in the bioreactor; then a cell culturemedium buffer is injected into the bioreactor to continuously culture the stem cells for 12 hours; and 3) a supernatant in the bioreactor is collected, and the supernatant undergoes ultracentrifugation to obtain a protein concentrate. According to the method for large-scale production of mesenchymal stem cell secretin, enzyme in cells and sulfhydryl groups in protein can be protected from being oxidized by adding beta-mercaptoethanol or monothioglycerol. With the addition of the leukemia inhibitory factor, the leukemia inhibitory factor can avoid stem cell differentiation and maintain stem cell pluripotency.

A cultivation method of mesenchymal stem cell secretin comprises the following steps: S1, taking a mesenchymal stem cell and adding into a bioreactor for cultivation, obtaining a target amount, and washing mesenchymal stem cells in the bioreactor with a double-antibody-containing PBS buffer solution;S2, adding a complete medium I and the double-antibody-containing PBS buffer solution into the bioreactor to continue cultivation; S3, collecting supernate in the bioreactor, adding a PCH flocculating agent into the supernate, and precipitating protein in the supernate; S4,putting a protein precipitate obtained in S3 into a semi-permeable membrane, and using deionized water to repeatedly wash the protein precipitate in the semi-permeable membrane; S5, utilizing the deionized water to load a mesenchymal container with protein, and obtaining a protein liquid as the mesenchymal stem cell secretin. The cultivation method not only can effectively improve the space utilization rate and reduce the usage amount of a nutrient medium, but also improves the protein purity and reduces the loss rate.

The present invention provides compositions and methods for preventing and treating gastrointestinal disorders by administering to a subject an effective amount of secretin either alone or in combination with an effective amount of oxytocin. The invention also provides compositions and methods for preventing and treating central nervous system disorders by administering to a subject an effective amount of secretin in combination with an effective amount of oxytocin. The invention further provides compositions and methods for treating and preventing a variety of autoimmune diseases by administering to a subject an effective amount of secretin in combination with an effective amount of oxytocin. Additionally, the invention provides compositions and methods for preventing and treating pain by administering to a subject using a combination of an effective amount of secretin and an effective amount of oxytocin. The invention also provides kits for use in treating and / or preventing gastrointestinal disorders, central nervous system disorders, autoimmune diseases and pain comprising a combination of secretin and oxytocin.

The invention provides a preparation method of a medical dressing, which includes preparation of secreted PLGA sustained-release microspheres, preparation of a hydrogel, preparation of an electrospunmembrane, and preparation of a stem cell secretion medical dressing. In the invention, a combination of sub-totipotent stem cell secretin, PLGA sustained-release microspheres and hyaluronic acid hydrogel is used, and the electrospun membrane is used as a carrier to prepare the medical dressing, the sub-totipotent stem cell secretion is rich in various active factors, and has a good repair effect on wounds; Experiments show that the medical dressing prepared by the invention has a good healing effect on both acute and chronic wounds. The medical dressing can adhere to the wound well, and the sub-totipotent stem cell secretin in the PLGA sustained-release microspheres is slowly released, which greatly improves the utilization rate of the secretion and the durability, the PLGA slow-release microspheres contain a larger amount of subtotipotent stem cell secretions, which reduces the number of dressing changes, avoids secondary trauma during the dressing change, and facilitates wound repair.

The invention relates generally to methods for treating pain associated with chronic pancreatitis in patients. The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising secretin and a pharmaceutically acceptable carrier.

Provided herein relate to modified or mutant forms of secretin and compositions comprising the same. In particular, the modified or mutant forms of secretin permits efficient capture and / or translocation of an analyte through the modified or mutant secretin nanopores. Methods for using unmodified secretin or the modified or mutant forms of secretin and compositions, for example, for characterizing an analyte, e.g., a target polynucleotide, are also provided.

The invention discloses a stem cell secretin for anti-aging and its preparation method and application. During the preparation, mesenchymal stem cells are collected, cultured for 2-5 days, the cultured cells are collected, washed with PBS buffer solution, and then added with water to lyse The lysate is obtained; the lysate is then centrifuged at low temperature, the supernatant is collected, and human albumin with a mass of 1-2% of the supernatant is added to obtain the stem cell secretin. Mesenchymal stem cells include bone marrow, umbilical cord, placenta and fat. The stem cell secretin prepared by the invention can have an anti-aging effect, and the stem cell secretin is derived from bone marrow mesenchymal stem cells. The present invention proves that the secretin, compared with the untreated one, can delay the senescence of human adult MSCs, so it has the potential of delaying senescence. The medicine of the present invention can be administered intravenously or locally.

It has been discovered that the neuropeptides secretin, oxytocin and vasopressin can be administered as therapeutic agents alone or in various combinations to treat dry eye and dry mouth. Based on these discoveries and the results described, certain claims are directed to pharmaceutical compositions formulated for topical oral or ophthalmic use comprising therapeutically or prophylactically effective amounts of the neuropeptides secretin, oxytocin and secretin alone, or in various combinations.

The invention discloses a sample preparation method for the sex hormone level determination of larval paralichthyidae fishes to young paralichthyidae fishes and comprises the following steps: a larval paralichthyidae fish or a young paralichthyidae fish is prepared, measured, skived after adding liquid nitrogen, ultrasonically grinded and evenly mixed with ethyl ether; a liquid phase is stored after centrifugation, a solid phase is evenly mixed with PBS buffering liquid and ethyl ether, and the liquid phase is stored after centrifugation; the liquid phase is evenly mixed, statically placed and delaminated; the delaminated liquid is placed into liquid nitrogen for being quickly cooled, and an organic phase is recycled; an aqueous phase is mixed with ethyl ether, statically placed, delaminated and quickly cooled in liquid nitrogen, and the organic phase is recycled, collected and placed in a stink cupboard, and then volatilized in a water bath at the temperature of 45 to 55 DEG C; the organic phase is dissolved in the PBS buffering liquid, stored at the temperature of minus 20 DEG C, and prepared for radioimmunoassay. The sample preparation method has simple operation process and stable result, can be used for the sample preparation of the sex hormone content determination of the larval paralichthyidae fishes to the young paralichthyidae fishes with the length of 6.5 cm, and is applicable to the internal secretin regulation and control research of other young flounder fishes even other marine fishes, thus having wide application range.